Zachary Moore, PhD

Director, Cadence Communications & Research. All opinions are my own.

[Noemi Reguart @NReguart]

#ESMO 2024. Outcomes by prior concurrent cCRT regimen and PCI use in the phase 3 ADRIATIC trial presented by Dr. S.Senan. Consolidation durvalumab consistent benefit in OS and PFS vs placebo in subgroups (PCI yes/no).

[David Gorski, MD, PhD @gorskon]

It’s about damned time. #Homeopathy is quackery. https://t.co/2Ta7jlKuEL

[H. Jack West, MD, FASCO @JackWestMD]

Riely: afatinib is now EGFR TKI of choice in squam NSCLC, but that's damning w/faint praise. EGFR TKIs are weak Rx for squam NSCLC. #ASCO15

[H. Jack West, MD, FASCO @JackWestMD]

Dr. Soria says afatinib should now be EGFR TKI of choice for squam NSCLC. I agree. Modest diffs, but clearly favor afatinib. #ASCO15

[ASCO @ASCO]

#ASCO15 Breaking News: First phase III study to show immunotherapy is effective against non-squamous NSCLC http://t.co/LtSpd7qlYi

[The ASCO Post @ASCOPost]

Nivolumab Extends Survival for Patients With Nonsquamous Non–Small Cell Lung Cancer http://t.co/HuRNK9Uf5K #LCSM #ASCO15

[OncLive.com @OncLive]

Palbociclib More Than Doubles PFS in Pretreated HR+/HER2- Breast Cancer http://t.co/91fbFLVU5z #ASCO15

[OncLive.com @OncLive]

Impressive phase II data presented at #ASCO15 for daratumumab will be submitted to the FDA http://t.co/UkfyQCkDso

[Merry-Jennifer Markham, MD, FACP, FASCO @DrMarkham]

#ASCO15 would not be possible without all of our brave and noble cancer patients who enroll on clinical trials. THANK YOU.

[Richard Schilsky @rschilsky]

#ASCO15 Porter calls for integrated practice units to improve care delivery and outcomes.

[CancerDotNet @CancerDotNet]

Great first day of #ASCO15! Looking for a round-up of today's research highlights? What it all means for patients: http://t.co/IhZ4Cqek0v

[Julie Gralow @jrgralow]

Congrats to @ASCO Distinguished Achievement award recipient, George Bosl. #asco2105

[Robert S Miller, MD, FACP, FASCO, FAMIA-he/him @rsm2800]

This is big: PD-1 blockade in tumors with mismatch repair deficiency http://t.co/PpmqtYHLcK #ASCO15

[Zachary Moore, PhD @z_phd]

Thanks for the free headshot, #ASCO15!

[Zachary Moore, PhD @z_phd]

Targeting "truncal" versus "branchal" mutations in RCC... A better paradigm to understanding biology? -James Larkin #ASCO15

[National Cancer Institute @theNCI]

Follow #ASCO15 for updates from the annual meeting of the American Society of Clinical Oncology (ASCO), which starts today in Chicago. @ASCO

[Oncology Tube @oncologytube]

Kidney Cancer Immunotherapy Q&A http://t.co/us5kcWeTWA

[ASCO @ASCO]

Wondering what to expect at #ASCO15? Here's one early-career oncologist's perspective: http://t.co/KuDcIApTHA

[Zachary Moore, PhD @z_phd]

The calm before the storm... #ASCO15

[Zachary Moore, PhD @z_phd]

The big Novartis/GSK swap fascinates me: http://t.co/xrVxC4RDcO